LAST VERIFIED 3 AUGUST 2026
Pogosh is a small, independent product in a market with some very large incumbents. The useful comparison is not "who is best" — it is which job you are trying to do. This page tries to be straight about that, including where Pogosh is the wrong tool.
Every claim below about another product was checked against that vendor’s own public pages in August 2026. Where something is not publicly disclosed, we say so rather than guess. Products change — tell us if something here is out of date.
Reference tools tell a clinician what to read. Pogosh tells your software what to order. You probably want both.
Most clinical software here answers a question you go and ask, or writes down a decision you already made. Pogosh sits in the gap between those two: it reads the chart and returns the specific, coded orders and routing that come next — as data your software can act on. That is a difference in purpose, not a claim to know more medicine than a reference library. It does not.
Deep, edited, citable topic reviews written for a clinician to read. This is a genuinely excellent category and Pogosh does not try to replace it — if you want to understand a condition thoroughly, these are better than Pogosh and will stay better.
Two things changed recently: between late 2025 and 2026 both EBSCO and Elsevier shipped real documented clinical-content APIs, and Elsevier’s ClinicalKey AI API even includes a differential-diagnosis endpoint. So "reference tools have no API" is no longer true.
These generate a differential from a presentation. This is the category closest to Pogosh, and it is worth being honest that it is well established — Isabel has offered a documented API since 2010 and also runs an education product off the same engine.
These listen to the encounter and produce documentation, and they are very good at it. The category is built on capture rather than recommendation: even the most advanced ordering feature works by recognising intent you have already spoken aloud. You have to know you want the CT in order to say it.
Built for the Medicare Appropriate Use Criteria mandate, mostly sold to hospitals or run by payers for prior authorisation. Worth knowing: that mandate is currently paused — in the CY2024 Physician Fee Schedule rule CMS paused the AUC program for reevaluation and rescinded the implementing regulations at 42 CFR 414.94, effective January 1, 2024. So this is a clinical choice today, not a compliance checkbox.
Only rows that are factually checkable. We have deliberately left out anything subjective — there is no "accuracy" row here, because no one in this market can substantiate one.
| Pogosh | Reference libraries | Diagnostic / DDx | Ambient scribes | |
|---|---|---|---|---|
| What it returns | Coded orders, routing, escalation, drafted note | Topic reviews, links, citations | Ranked differential | A note from the conversation |
| Machine-readable codes | LOINC + RadLex + ICD-10 | Mostly prose and links | Varies by vendor | Note text; some order staging |
| Accounts for studies already done | Yes, by design | Not applicable | Varies | Only if spoken aloud |
| Developer API | Yes, evaluation key issued directly | Yes — but a contract or institutional registration is required | Yes for some, access gated | Partner programs, allow-list gated |
| API pricing published | Yes | No | Generally no | No |
| Per-seat annual cost | Higher — $149–299 / month | Lower — DynaMed $399/yr, ClinicalKey AI $349/yr. UpToDate does not publish list pricing | Not applicable | Not applicable |
| Works with a custom-built EHR | Yes — REST, any client. OpenEMR module available | Contract dependent; none lists an OpenEMR module | Contract dependent | Usually targets major commercial EHRs |
| Independent validation and third-party evaluation | None published yet — validation partner program starting | Substantial. DynaMed holds 2025 Best in KLAS for point-of-care clinical reference; all have long institutional track records | Long established and widely used | Established products |
On cost: read that row honestly. If what you need is one clinician reading reference content, a subscription library is cheaper than Pogosh and we would rather you knew that now. Pogosh is priced as a practice- or application-level API rather than a per-clinician reading seat, which is a different unit of purchase — but on a naive per-seat basis it is the more expensive option.
Longer, single-vendor comparisons — each one includes the cases where the other product is the better choice.
Column groups describe the general shape of each category as published by its vendors in August 2026; individual products differ. "API pricing published" means a rate card a developer can read without contacting sales. We have deliberately left out any row comparing BAA terms, security posture, or PHI handling, because we could not verify those per vendor and would rather omit a row than guess about someone else’s compliance. If you represent one of these products and something here is wrong, email signal@gighz.com and we will correct it.
No. Those are reference libraries built for reading — deep, edited, citable topic reviews. Pogosh does not try to replace that. Pogosh returns structured, coded orders for a specific patient so software can act on them. Many clinicians will reasonably use both.
Ambient scribes capture what was said and turn it into documentation. They are excellent at that. But they start from a decision you have already made — you have to know you want the CT before you say it. Pogosh works the other direction: it reads the chart and suggests what to order. The two are complementary rather than competing.
Yes. That is one of the clearest practical differences. As of August 2026, the major clinical reference APIs — UpToDate Connect, EBSCO MedsAPI, and Elsevier ClinicalKey AI — all require a contract or institutional registration, and none publishes API pricing. Pogosh issues evaluation keys directly to developers.
Pogosh does not reproduce the ACR Appropriateness Criteria rating tables. Those are the ACR intellectual property and commercial use is licensed case-by-case. Pogosh presents its imaging guidance in its own neutral terms — Preferred, Consider, Avoid — and cites the general evidence basis rather than republishing another organisation’s tables. This is a segment-wide licensing constraint rather than something specific to Pogosh: the other products in this space do not republish those tables either.
No. The Appropriate Use Criteria program under PAMA is paused, not active. In the CY2024 Physician Fee Schedule final rule CMS paused implementation for reevaluation and rescinded the implementing regulations at 42 CFR 414.94, effective January 1, 2024. Imaging decision support is therefore a clinical and operational choice today, not a compliance requirement.
It is not an encyclopedic reference you read for depth. It has no brand recognition and no published user reviews yet. Independent clinical validation is in progress through a partner program rather than already published. And it is built by a small independent team — if your procurement requires a large established vendor, that is a real consideration.
Paste a real case and judge the reasoning yourself.